Home
>
US Stocks
>
Dynavax Technologies Corp.
Dynavax Technologies Corp.
DVAX

Dynavax Technologies Corp. (DVAX)

$13.153.3%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$12.95
Today Low/High$12.82 / $13.97
52 Week Low/High$4.93 / $21.39
P/E ratio-37.62
Market Cap$1.62B

Company Details

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
OrganisationDynavax Technologies Corp.
HeadquatersEmeryville, California, US
IndustryHealth Technology
CEORyan Spencer

Discover more

Frequently Asked Questions

What is Dynavax Technologies Corp. (DVAX) share price today?

Can Indians buy Dynavax Technologies Corp. (DVAX) shares?

How can I buy Dynavax Technologies Corp. (DVAX) shares from India?

Can Fractional shares of Dynavax Technologies Corp. (DVAX) be purchased?

What are the documents required to start investing in Dynavax Technologies Corp. (DVAX) stocks?